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Abstract
 The study of glycomics is a novel and fascinating approach for the 
development of biomarkers. It has become clear that in the field of 
liver disease specific glycomic patters are present in specific disease 
states, which has led to the development of diagnostic biomarkers. 
In this manuscript, we will describe two new applications of this 
technology for the development of prognostic biomarkers. The first 
biomarker is associated with the risk of hepatocellular carcinoma 
development in patients with compensated cirrhosis. The second 
biomarker is present in perfusate and is related to the risk of 
primary non function occurrence after liver transplantation. The 
technology used for these biomarkers could easily be implemented 
on routine capillary electrophoresis equipment. (Acta gastroenterol. 
belg., 2019, 82, 309-313). 
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Glycomics : an introduction
 One of the most important medical evolutions of the 
last decade is the development of personalized medicine. 
The success of personalized medicine depends on having 
accurate diagnostic tests that identify patients who can 
benefit from targeted treatment strategies (1). Over the 
last years, a large range of different omics have led to the 
development of valuable biomarkers, based on genomics, 
proteomics, transcriptomics, metabolomics etc. (2). Only 
few attention has been paid to the study of glycomics, 
an attractive though not well known technology that can 
lead to the development of biomarkers in a variety of 
diseases (3-5).
 In human cells proteins are frequently modified 
with complex glycan structures. This process, called 
glycosylation, is the most frequent posttranslational 
modification (6) Three major types of glycosylation have 
been observed : N-linked glycosylation of asparaginases 
(6) O-linked glycosylation of serine and threonine (7) 
and glycosylphosphatidyl inositol derivatization of the 
carboxyl-terminal carboxyl groups (8). Here, we will 
focus on the N-glycosylation of human proteins. 
 N-glycosylation is essential for cell viability. It is 
strictly regulated by specific enzymes (9) and at least 
half of the genes functioning in this biosynthetic pathway 
have been conserved through evolution. These glycan 
structures are involved in diverse biological processes 
including protein folding and conformation, cell structure 
and stability and cell-matrix and cell-cell interaction (9).
 Alterations in the abundance of particular N-glycans 
reflect an altered physiological state. This makes 
N-glycans particularly attractive for biomarker deve-
lopment. Furthermore, N-glycoproteins are highly 
regulated during growth and differentiation and 
alterations in protein N-glycosylation patterns correlate 
with developmental programs like morphogenesis, 
proliferation and apoptosis (10). 
 Over the last 10 years, it has become clear that serum 
proteins display typical glycoalterations in humans with 
chronic liver disease as opposed to healthy adults (3). 
This observation is supported by the fact that the majority 
of circulatory proteins are secreted by the liver and thus 
these glycoalterations can reflect pathological processes 
in the liver. A minority of serum glycans are attached to 
IgG and are secreted by B-cells (11,12), and are involved 
in inflammatory processes.
 Standardized protocols for sugar labeling and its 
application on a DNA sequencer using DNA sequencer 
assisted fluorophore assisted capillary electrophoresis 
(DSA-FACE) has provided researchers with a technical 
environment that allows glycome analysis of the liver 
patient (13,14).
 This pioneering work resulted more than 10 years 
ago in the development of the first glycomics-based 
biomarker for the diagnosis of fibrosis and cirrhosis, 
called the GlycoFibroTest (11) and the GlycoCirrhoTest 
(15,16). Other technologies including mass spectrometry, 
chromatography and lectin based assays have been 
applied for glycomic analysis but these cannot combine 
a high diagnostic accuracy with high throughput 
abilities at an affordable cost, as is needed for clinical 
implementation (13). 
Glycomics for diagnosis of liver disease
 Although non-invasive markers for the quantification 
of liver fibrosis have become mainstream in clinical 
practice during the last years (17), invasive liver 
biopsy was until then the standard of care for fibrosis 
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Risk of HCC development in compensated cirrhosis
 Liver cancer is the sixth most common cancer 
worldwide and the fourth cause of cancer-related death 
(36). Cirrhosis is the main risk factor for the development 
of HCC. Although European (37) and American (38) 
guidelines advocate ultrasonography-based screening 
for early HCC with or without measurement of AFP, 
adherence to these screening programs is disappointingly 
low (39) and the incidence of HCC is rising (36).
 Recently, we showed that the GlycoCirrhoTest, a 
glycomics-based serum marker, could radically change 
this approach. While the current screening strategy is 
a one-size-fits-all approach, we showed that the use of 
the GlycoCirrhoTest was able to assess the risk of HCC 
development in patients with compensated cirrhosis and 
this could allow for a personalized screening protocol.
 In a French cohort of 125 patients, a single measu-
rement of the GlycoCirrhoTest, which is based on 
the measurement of 2 single glycans (a bisecting 
N-acetylglucosamine (GlcNAc)- containing N-glycan 
and a triantennary N-glycan) on serum glycoproteins 
was able to distinguish (Hazard ratio 12.1 ; 95% CI, 
2.8–51.6 ; p< 0.01) between patients with a high and a 
low risk of HCC development during the following 7 
years (40) (Figure 1). The median follow-up time in this 
study was 6.4 years. In a multivariate Cox Regression 
model including GlycoCirrhoTest, AFP and FIB-4 only 
GlycoCirrhoTest showed a significant and independent 
association with HCC development during follow up. 
 This finding is supported by a strong pathophysiological 
rationale. The enzyme N-acetyl glucosaminyl trans-
ferase III responsible for the formation of bisecting 
GlcNAc residues, which are the driving glycans of the 
GlycoCirrhoTest, is increasingly expressed in cirrhotic 
nodules (41,42). It is conceivable that with more 
hepatocytes actively dividing in such nodules, the risk 
for propagation of oncogenic mutations increases and 
hence the risk for HCC rises. Therefore a true marker for 
such nodular regeneration in liver cirrhosis should also 
be a good risk marker for HCC, as validated here for the 
GlycoCirrhoTest (16).
 The findings of this study could be the basis for a 
radical change in the approach of the cirrhotic patient. 
In this era of personalized medicine such tools are highly 
valuable. Based on the result of the GlycoCirrhoTest, 
patients could be stratified in a low-risk or high-risk group 
for HCC development. These patients could be offered 
personalized screening regimens. For example, this study 
teaches us that patients with a low GlycoCirrhoTest value 
have an extremely low chance of HCC development 
(less than 5%) in the first 3 years of follow-up, whereas 
this risk is higher than 40% in the patients with a high 
GlycoCirrhoTest value. It could make sense to offer 
the GlycoCirrhoTest low patients a yearly screening 
examination, whereas the GlycoCirrhoTest High group 
should be followed every six months as it is performed 
now.
and cirrhosis assessment (18). Making use of different 
technical approaches, several groups have shown 
consistent changes in the whole serum glycome in patients 
with chronic liver disease, according to increasing 
levels of liver fibrosis leading to the development of 
specific biomarkers for liver fibrosis (11,12,19,20) and 
cirrhosis (16). Glycomic profiling of serum of patients 
with hepatocellular carcinoma (HCC) has also lead to 
consisting observations. These findings include increased 
core fucosylation (21-24) and multibranching glycans 
(25; 26). The use of alpha-foeto-protein-L3 (AFP-L3), 
the fucosylated L3 fraction of AFP could dramatically 
increase the performance of this widely used biomarker 
(27).
 In the field of non-alcoholic steatohepatitis  (NASH) 
there is an ongoing need for biomarkers that can 
differentiate between simple steatosis and NASH (28). 
We have shown (29-31), amongst others (32-35), that the 
serum glycomic profiling can identify NASH patients 
among patients with simple steatosis. 
Glycomics as prognostic biomarkers in liver disease
 Over the last year, we have shifted our attention from 
the development of diagnostic biomarkers to prognostic 
biomarkers, based on glycomic profiling. 
Figure 1. — Cumulative incidence curve representing the risk 
for developing hepatocellular carcinoma according to value of 
the GlycoCirrhoTest (adapted from Verhelst et al. (40)). The 
cohort was divided according to the GlycoCirrhoTest threshold 
and monitored for the appearance of hepatocellular carcinoma. 
Blue line, patients with a GlycoCirrhoTest value <0.2; green 
line, patients with a GlycoCirrhoTest above or equal to the 
threshold of 0.2. These patients show an increased risk for 
hepatocellular carcinoma development (HR ¼ 5.1; 95% CI, 
2.2–11.7; P < 0.001). Censored cases (as indicated by crosses 
on the cumulative incidence curves) died, underwent liver 
transplantation, or were lost to follow-up.
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reports that the undergalactosylated glycans in serum 
are present on IgG and not on liver-derived proteins 
(11,12). We measured IgG levels in perfusate and found 
their presence in the perfusate fluid (unpublished data). 
The levels of IgG were not increased in PNF patients 
compared to the non-PNF group. This implies that the 
undergalactosylation in this perfusate is a real glycomic 
alteration. The pathophysiological rationale is far from 
clear. However, it makes sense that the failing liver is a 
“stressed” organ, eg. by increased ischemia-reperfusion 
injury, with an important upregulation of inflammatory 
pathways, which is reflected by the increased abundance 
of undergalactosylated glycans. These livers are suffering 
and fail to develop the regeneration capacity to start 
functioning after liver transplantation.
 Third, the accuracy for the prediction of PNF was 
extremely high (100%). On the other hand we found 
no clear relationship between the perfusate glycome 
profile and the occurrence of early allograft dysfunction 
(EAD). We speculate that this might be related to the 
fact that EAD is a complex and multifactorial syndrome 
that is not only related to the quality of the donor liver 
graft but also to recipient characteristics and intra- and 
postoperative events. This information will of course not 
be captured in the pretransplant glycome profile. On the 
other hand, PNF is mainly related to very low quality 
grafts (45), which can be captured quite convincingly by 
the glycome profile.
 If we can confirm the predictive power of perfusate 
glycomics for the occurrence of PNF this could have 
an important impact on allocation practices. Organ 
allocation these days is more “art” than “science”. 
Our tools for graft assessment are limited to a clinical 
appreciation and the use of scores like the Donor Risk 
Index (DRI) or Eurotransplant-DRI (46,47), which lack 
the prognostic power in individual patients. On the other 
hand, we are faced with a decreasing quality of organs. 
All strategies that aim at expanding the donor pool like 
the use of DCD donors or the use of elderly donors have 
an additional negative impact on donor quality (48). 
 Yet, these results need to be interpreted with caution, as 
this was a monocentric study with a considerable but not 
extremely high number of patients included. However, 
from a statistical point of view the use of cross-validation 
and bootstrap validation confirmed the strong association 
of GlycoCirrhoTest with HCC development. This is a 
unique cohort with clinical data and serum that has been 
collected prospectively with a median follow-up time of 
almost 7 years. The search for similar cohorts that would 
allow validation has been difficult and disappointing. 
A prospective validation will take several years before 
useful results will be available. 
 The next step will be a pharmaco-economic evaluation 
of this strategy. If this strategy proves to be non-inferior to 
the current screening strategy, the financial repercussions 
could be very attractive. The reduction of visits by 50% in 
the GlycoCirrhoTest Low patients represents a real cost 
benefit, especially in countries where health insurance is 
not universal and where the distance to medical care can 
be larger than in Belgium.
 In conclusion, the observation that GlycoCirrhoTest 
is a predictor of HCC risk in patients with compensated 
cirrhosis could be a highly-expected game-changer that 
answers the desire for personalized medicine and cost 
reduction in modern medicine.
Outcome after liver transplantation
 For the first time glycomic profiling of perfusate was 
performed using DNA sequencer assisted fluorophore 
assisted capillary electrophoresis on a DNA sequencer 
as developed by the team of Callewaert et al. (14,16). 
From a theoretical point of view, perfusate analysis 
is an attractive alternative for liver biopsy or serum 
markers for the assessment of viability of the liver in 
liver transplantation. Perfusate is believed to represent 
the condition of the entire liver parenchyma and it is 
easy to collect in large volumes. However, only few 
perfusate markers have previously shown any value in 
the prediction of graft and patient outcome after liver 
transplantation (43). Our study confirms the potential of 
perfusate analysis to guide donor allocation. In a cohort 
of 66 liver transplant patients, three patients developed 
primary non function (PNF) and based on the glycomic 
signature of perfusate before liver transplantation we 
were able to predict the occurrence of PNF after liver 
transplantation with 100% accuracy (44). These findings 
were validated in an independent cohort (Figure 2). 
 A few reflections should be made in the appraisal of these 
results. First, although this multicentric study provides a 
strong proof-of-concept, a larger multicentric prospective 
validation is needed (and ongoing). Second, the glycome 
signature is based on an increase of undergalactosylated 
glycans. The increased abundance of undergalactosylated 
glycans is a phenomenon that we also encountered in 
NASH patients (30) and in the serum of liver transplant 
patients that are at greater risk of early graft loss (Verhelst 
et al, unpublished results). We know from previous 
Figure 2. — Overview of the relative abundance of NGA2F, 
an undergalactosylated glycan in patients who developed 
primary non function (PNF) after liver transplantation. 
A. NGA2F shows 100% accuracy for prediction of PNF 
(p<0.001). p values were calculated using Mann Whitney U- 
test. B. Structure of NGA2F. The symbols used in the structural 
formulas are as follows: blue square, b-linked GlcNAc; red 
triangle indicates alpha,beta-1,3,6-linked fucose; green circle, 
a/b-linked mannose. PNF: primary non function. EAD: early 
allograft dysfunction. Adapted from Verhelst et al. (44).
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licensed to Helena Biosciences. X. Verhelst and H. Van 
Vlierberghe are listed as a co-inventors on a patent on the 
perfusate marker for PNF as described in the manuscript 
that is owned by Ghent University. 
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 A reliable biomarker that can predict organ failure 
with 100% certainty could help us to discard these unsafe 
organs from the donor pool and safely use donor organs 
where the clinician is in doubt regarding the quality. We 
remind the reader that our data were obtained in real 
clinical practice where all organs, including the PNF 
patients, were considered safe by the transplant team.
 Although we are convinced of the real clinical value 
of this glycomic marker for PNF, the current approach as 
published in the study reveals a major obstacle towards 
implementation in clinical practice. The technique that 
we used in the publication has a turn-around time of 
48 hours. In a concept where donor graft quality would 
be assessed before liver transplantation, this does not 
make any sense and makes this technique obsolete. New 
technical developments should decrease the turnover 
time to an acceptable 30 minutes (Callewaert et al., 
unpublished data). 
Conclusion
 In this work we explored the potential of glycomics 
to detect prognostic biomarkers in liver disease and 
liver transplantation. First we demonstrated that the 
GlycoCirrhoTest, a biomarker that was formerly deve-
loped for the diagnosis of cirrhosis, is not only a diagnostic 
marker of cirrhosis, but also a prognostic marker that can 
predict whether a patient with com-pensated cirrhosis 
has a low or a high risk to develop HCC. This is a new 
tool that could be used in the follow up of patients with 
cirrhosis, as these patients need six-monthly screening 
for HCC by ultrasonography. This GlycoCirrhoTest 
could help in the development of personalized screening 
protocols for cirrhotic patients according to the value of 
this test.
 In the second section we assessed the potential value of 
glycomics to develop prognostic biomarkers in the field 
of liver transplantation. We showed that it was technically 
feasible to measure glycome profiles on perfusate, the 
fluid in which the liver is transported from the organ donor 
to the liver recipient. We successfully identified a specific 
glycome signature that is 100% predictive of a patient’s 
risk for developing primary non-function, a dramatic 
complication in the first hours upon liver transplantation 
that requires urgent retransplantation. This biomarker 
could prevent the transplantation of unsafe donor livers. 
In conclusion, the work described here adds to the 
increasing evidence that the whole serum protein glycome 
is a robust surrogate marker of processes that affect the 
liver. Furthermore, we were able to identify several 
potential prognostic biomarkers with real clinical utility 
in cirrhosis and liver transplantation. Validation studies 
of the most promising glycomics-based biomarkers are 
ongoing.
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